All GLP-1 therapy works best when combined with comprehensive lifestyle changes and personalized medical support
For investors, it demonstrates that the opportunity may be even broader and more durable than anticipated
Other substituents: modifications can fine-tune potency and selectivity, potentially reducing off-target activity
Given its dual mechanism and promising preclinical results, AMG-133 is anticipated to be a significant advancement in obesity and metabolic disease management
doi: 10.1016/j.tem.2021.12.001, 87 Moreno-YruelaC.ZhangD.WeiW.BaekM.LiuW.GaoJ.et al
trials used a stepwise dose-escalation approach at Q4W In TRIUMPH-3, 12mg reduced TGs, non-HDL cholesterol, systolic BP, waist circumference, & hsCRP by 37%, 16.5%, 9.3mmHg, 19cm, & 51.2%, respectively